Advertisement
Screener

ZYMEWORKS INC. (ZYME) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

ZYMEWORKS INC. Operating Cash Flow

ZYMEWORKS INC. (ZYME) reported Operating Cash Flow of -$77.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • ZYMEWORKS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.95M, a 364.62% decline year-over-year.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$45.72M.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$10.26M.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$31.41M.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for fiscal 2025 was -$33.01M.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for fiscal 2024 was -$110.06M.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for fiscal 2023 was -$118.32M, a 182.11% decline from fiscal 2022.
  • ZYMEWORKS INC. net cash provided by (used in) operating activities for fiscal 2022 was $144.11M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$31.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$77.67M
10-Q · filed 2026-08-06
-$87.92M
derived: sum of 3 quarters · filed 2026-08-06
-$119.34M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$45.72M
10-Q · filed 2026-05-07
-$55.98M
derived: sum of 2 quarters · filed 2026-05-07
-$87.39M
derived: sum of 3 quarters · filed 2026-05-07
-$75.32M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$10.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$41.67M
derived: sum of 2 quarters · filed 2026-03-02
-$29.60M
derived: sum of 3 quarters · filed 2026-08-06
-$33.01M
10-K · filed 2026-03-02
2025-09-30-$31.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$19.34M
derived: sum of 2 quarters · filed 2026-08-06
-$22.75M
10-Q · filed 2025-11-06
-$64.26M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$12.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$8.67M
10-Q · filed 2026-08-06
-$32.84M
derived: sum of 3 quarters · filed 2026-08-06
-$38.72M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$3.41M
10-Q · filed 2026-05-07
-$44.92M
derived: sum of 2 quarters · filed 2026-05-07
-$50.80M
derived: sum of 3 quarters · filed 2026-05-07
-$75.79M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$41.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$47.39M
derived: sum of 2 quarters · filed 2026-03-02
-$72.38M
derived: sum of 3 quarters · filed 2026-03-02
-$110.06M
10-K · filed 2026-03-02
-$110.04M
10-K · filed 2025-03-05
2024-09-30-$5.88M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$30.87M
derived: sum of 2 quarters · filed 2025-11-06
-$68.55M
10-Q · filed 2025-11-06
-$68.54M
10-Q · filed 2024-10-31
-$54.62M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30-$24.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$62.67M
10-Q · filed 2025-08-07
-$62.66M
10-Q · filed 2024-08-01
-$48.73M
derived: sum of 3 quarters · filed 2026-03-02
-$91.40M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31-$37.67M
10-Q · filed 2025-05-08
-$37.67M
10-Q · filed 2024-05-02
-$23.74M
derived: sum of 2 quarters · filed 2026-03-02
-$66.41M
derived: sum of 3 quarters · filed 2026-03-02
-$72.81M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31$13.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
-$28.73M
derived: sum of 2 quarters · filed 2026-03-02
-$35.13M
derived: sum of 3 quarters · filed 2026-03-02
-$118.32M
10-K · filed 2026-03-02
-$118.30M
10-K · filed 2024-03-06
2023-09-30-$42.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31
-$49.07M
derived: sum of 2 quarters · filed 2024-10-31
-$132.26M
10-Q · filed 2024-10-31
$195.10M
derived: sum of 4 quarters · filed 2025-03-05
2023-06-30-$6.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$89.59M
10-Q · filed 2024-08-01
$237.77M
derived: sum of 3 quarters · filed 2025-03-05
$164.75M
derived: sum of 4 quarters · filed 2025-03-05
2023-03-31-$83.19M
10-Q · filed 2024-05-02
$244.17M
derived: sum of 2 quarters · filed 2025-03-05
$171.15M
derived: sum of 3 quarters · filed 2025-03-05
$116.33M
derived: sum of 4 quarters · filed 2025-03-05
2022-12-31$327.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
$254.34M
derived: sum of 2 quarters · filed 2025-03-05
$199.52M
derived: sum of 3 quarters · filed 2025-03-05
$144.11M
10-K · filed 2025-03-05
2022-09-30-$73.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$127.84M
derived: sum of 2 quarters · filed 2023-11-07
-$183.25M
10-Q · filed 2023-11-07
-$233.76M
derived: sum of 4 quarters · filed 2024-03-06
2022-06-30-$54.82M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$110.24M
10-Q · filed 2023-08-10
-$160.75M
derived: sum of 3 quarters · filed 2024-03-06
2022-03-31-$55.41M
10-Q · filed 2023-05-08
-$105.92M
derived: sum of 2 quarters · filed 2024-03-06
2021-12-31-$50.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
-$192.45M
10-K · filed 2024-03-06
2021-09-30-$141.94M
10-Q · filed 2022-11-08
2020-12-31-$151.40M
10-K · filed 2023-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
COMPASS Pathways plc (CMPS)$1.812B-4.87
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Septerna, Inc. (SEPN)United States$1.783B-63.01
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Xencor Inc (XNCR)United States$1.776B-7.33